Lab Tests Online would not be possible without the financial support and commitment to public service of the following companies. Each company recognizes the importance of engaging patients through a greater understanding of testing and regularly supports the efforts of the laboratory profession.
PROFESSIONAL CO-OP, an original model for laboratory testing, launched in 2001 to support clinicians in all walks of medicine. PCS provides appropriately licensed clinicians with access to major lab services for a fraction of the typical costs with service that exceeds expectations. There are no fees to join and no minimums. Our staff is knowledgeable, professional, and experienced in handling the issues and problems commonly seen indiagnostic testing. PCS allows the clinician to focus on what's most important, patient care!
Bio-Rad Laboratories has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for clinical diagnostic customers. Known for our commitment to quality and customer service, we offer a broad diagnostic portfolio: Blood Bank Blood-group serology reagents and automation; Chromogenic Media; Diabetes, Hemoglobinopathy Testing; HIV tests for screening, rapid differentiation and supplemental tests; BioPlex® 2200 System, fully-automated, high-volume random-access, multiplex analyzer. EVOLIS™ microplate sytem. PhD™ System for EIA/IFA. Infectious disease and autoimmune disease methods and assays; Quality Control: Reliable, high quality materials, robust QC data management, connectivity solutions, QC educational series and the industry’s largest QC support team.
Fujirebio Diagnostics, Inc. is a world leader in the production of in vitro diagnostics and the gold standard manufacturer of cancer biomarker assays worldwide. Biomarkers available from Fujirebio Diagnostics include: CA125II™, CA19-9™, CA15-3®, ProGRP, NSE, SCC, S100, CA 242, CA72-4©, CYFRA21-1™, and HE4, the first FDA cleared biomarker in 25 years for ovarian cancer management. Now cleared in the US is ROMA™ (Risk of Malignancy Algorithm). ROMA™ combines CA125 + HE4 to compute likelihood of ovarian malignancy.
Sysmex is a global leader in hematology laboratory blood analyzers and a frontrunner in clinical diagnostics, automation and information systems. The Sysmex solution – fully automated hematology, coagulation, and urinalysis instruments connected to laboratory information systems – delivers a high level of clinical accuracy, quality and reliability. Our advanced hematology analyzers produce extended CBC results including our proprietary Advanced Clinical Parameters (ACPs) to aid in the detection of hematological conditions including infection and the ability to monitor anemia. Serving laboratories for 40 years in more than 150 countries, Sysmex focuses on extending the boundaries of diagnostic science while keeping the patient top of mind. Visit www.sysmex.com/us
PAML is a medical reference laboratory serving physicians, hospitals, members of the community, employers, and other allied health professionals. Currently, PAML is ranked among the top clinical reference laboratories in the nation and is considered an industry leader in joint venture partnerships with community-based hospitals.
Wako was established more than 90 years ago as a manufacturer and distributor of high quality laboratory reagents. Wako has since evolved into a valued provider of unique automatable assays for diagnostic clinical use and a dedicated OEM partner. Most recently, with the launch of the μTASWako i30 instrument and AFP-L3 and DCP biomarkers for liver cancer risk assessment, Wako has also become a leader in system and automated assay development. With a global presence, Wako Diagnostics is known for offering "best in class" products for the chemistry and diagnostic reagent industries.
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases.
Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.
Alexion's metabolic franchise includes a therapy for the treatment of hypophosphatasia (HPP), a systemic metabolic disease whose biochemical hallmark is low alkaline phosphatase (ALP) activity.